Is Flunitrazepam 1mg tablets a controlled drug in the UK?

Yes, Flunitrazepam 1mg tablets is classified as Schedule 3 (CD No Register) under the UK Misuse of Drugs Regulations. This means there are special legal requirements for prescribing, dispensing, and storing this medicine. (Source: NHS dm+d, UK Misuse of Drugs Regulations 2001)

What should I avoid while taking Flunitrazepam 1mg tablets?

Avoid alcohol. Avoid grapefruit products. Limit caffeine intake. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Flunitrazepam 1mg tablets?

Flunitrazepam 1mg tablets is classified as a Invalid to prescribe in NHS primary care in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Flunitrazepam 1mg tablets?

Flunitrazepam 1mg tablets is the generic name. It is available under brand names including: Rohypnol 1mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Flunitrazepam 1mg tablets

Tablet

1mg

Oral

Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia.

Active ingredients:

Flunitrazepam

CD Schedule 3

Some safe custody exemptions; written records required

details

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.01.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05CD03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Flunitrazepam

1 safety notice

Schedule 3

Legal requirements and restrictions

Medicines with lower misuse potential than Schedule 2. Subject to special prescription requirements but reduced record-keeping.

Legal requirements

Safe custody requirements apply (locked storage)
No controlled drugs register required
Prescriptions valid for 28 days
Can be emergency supplied by pharmacists

Other medicines in this category

Buprenorphine, Tramadol injections, Midazolam

View full UK controlled drugs list

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Flunitrazepam

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Flunitrazepam

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Flunitrazepam on the MHRA register

Rohypnol 1mg tablets

Roche Products Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

1 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Midazolam 500mg/500ml solution for infusion bottles

Infusion

500mg/500ml

Same therapeutic group

Remimazolam 50mg powder for solution for injection vials

Injection

50mg

Same therapeutic group

Midazolam 2.5mg/0.25ml oromucosal solution pre-filled oral syringes sugar free

Other

2.5mg/0.25ml

Same therapeutic group

Midazolam 5mg/0.5ml oromucosal solution pre-filled oral syringes sugar free

Other

5mg/0.5ml

Same therapeutic group

Midazolam 7.5mg/0.75ml oromucosal solution pre-filled oral syringes sugar free

Other

7.5mg/0.75ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Flunitrazepam

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Flunitrazepam

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42129211000001102

dm+d ID

42129211000001102

VTM (Virtual Therapeutic Moiety)

775988007

VMP (Virtual Medicinal Product)

42129211000001102

BNF code

04010100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05CD03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

2 found

Half-life

18-26 hours

Mechanism

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which med…

Food interactions

4 warnings

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

50%

50% (suppository) and 64-77% (oral)

Half-life

18-26 hours

18-26 hours

Metabolism

Hepatic.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Illicit

Small molecule

About this compound

Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.

Properties:

solid

Avg. mass: 313.28 Da

DrugBank indication

For short-term treatment of severe insomnias, that are not responsive to other hypnotics.

Also known as(140)

Flunitrazepam

Flunitrazepamum

GABA(A) receptor subunit alpha-1

GABAAR subunit alpha-1

GABA(A) receptor subunit alpha-2

GABAAR subunit alpha-2

GABA(A) receptor subunit alpha-3

GABAAR subunit alpha-3

Dosage forms(6)

Capsule (Oral) — 2 MG

Solution / drops — 0.2 %

Tablet, film coated (Oral) — 1 mg

Tablet, film coated (Oral)

Tablet (Oral) — 2 MG

Tablet (Oral) — 1 MG

Molecular properties(18)

Drug interactions(1134)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Hydrocodone

Moderate

DB00956

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Flunitrazepam can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Flunitrazepam may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Mirtazapine

Moderate

DB00370

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Orphenadrine

Moderate

DB01173

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Pramipexole

Moderate

DB00413

Flunitrazepam may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Flunitrazepam may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Flunitrazepam may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Flunitrazepam.

Check this interaction

Suvorexant

Moderate

DB09034

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Thalidomide

Moderate

DB01041

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Clozapine

Unknown severity

DB00363

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clozapine.

Check this interaction

Methadone

Moderate

DB00333

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Check this interaction

Sodium oxybate

Moderate

DB09072

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Teduglutide

Unknown severity

DB08900

The serum concentration of Flunitrazepam can be increased when it is combined with Teduglutide.

Check this interaction

Yohimbine

Moderate

DB01392

The therapeutic efficacy of Flunitrazepam can be increased when used in combination with Yohimbine.

Check this interaction

Irinotecan

Unknown severity

DB00762

The risk or severity of neutropenia can be increased when Flunitrazepam is combined with Irinotecan.

Check this interaction

Flumazenil

Moderate

DB01205

Flumazenil may decrease the sedative activities of Flunitrazepam.

Check this interaction

Ethanol

Moderate

DB00898

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Azelastine

Moderate

DB00972

Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Check this interaction

Brimonidine

Moderate

DB00484

Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.

Check this interaction

Zimelidine

Unknown severity

DB04832

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zimelidine.

Check this interaction

Dapoxetine

Unknown severity

DB04884

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dapoxetine.

Check this interaction

Seproxetine

Unknown severity

DB06731

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Seproxetine.

Check this interaction

Fluvoxamine

Unknown severity

DB00176

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluvoxamine.

Check this interaction

Citalopram

Unknown severity

DB00215

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Citalopram.

Check this interaction

Duloxetine

Unknown severity

DB00476

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Duloxetine.

Check this interaction

Trazodone

Unknown severity

DB00656

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trazodone.

Check this interaction

Paroxetine

Unknown severity

DB00715

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Paroxetine.

Check this interaction

Sibutramine

Unknown severity

DB01105

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Sibutramine.

Check this interaction

Escitalopram

Unknown severity

DB01175

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Escitalopram.

Check this interaction

Milnacipran

Unknown severity

DB04896

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Milnacipran.

Check this interaction

Desvenlafaxine

Unknown severity

DB06700

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desvenlafaxine.

Check this interaction

Levomilnacipran

Unknown severity

DB08918

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levomilnacipran.

Check this interaction

Indalpine

Unknown severity

DB08953

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Indalpine.

Check this interaction

Ritanserin

Unknown severity

DB12693

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ritanserin.

Check this interaction

Alaproclate

Unknown severity

DB13233

The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Alaproclate.

Check this interaction

Cyproheptadine

Unknown severity

DB00434

The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Flunitrazepam.

Check this interaction

Showing 50 of 1134 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Avoid Grapefruit

Avoid grapefruit products.

Caffeine Notice

Limit caffeine intake.

Take With Food

Take with food.

Toxicity & overdose

Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.

How it works

Mechanism of action

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Pharmacodynamics

Flunitrazepam is a powerful hypnotic drug that is a benzodiazepine derivative. It has powerful hypnotic, sedative, anxiolytic, and skeletal muscle relaxant properties. The drug is sometimes used as a date rape drug. In the United States, the drug has not been approved by the Food and Drug Administration for medical use, and is considered to be an illegal drug. It has however been approved in the United Kingdom and other countries.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

50% (suppository) and 64-77% (oral)

Half-life

18-26 hours

Metabolism

Hepatic.

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Gamma-aminobutyric acid receptor subunit theta

BE0004797

GABRQ

positive allosteric modulator

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Theta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:10449790 PMID:16412217
GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interfaces (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient PMID:10449790 PMID:16412217

Gamma-aminobutyric acid receptor subunit gamma-3

BE0008668

GABRG3

ligand

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Gamma subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (By similarity). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride across the cell membrane down their electrochemical gradient (By similarity)

Translocator protein

BE0000736

TSPO

agonist

Specific functionandrogen binding

Cellular location

Mitochondrion membrane

General function & pharmacology

Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism PMID:24814875, but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis.

Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides PMID:1847678

Metabolizing enzymes(9)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2A6Cytochrome P450 2A6

substrate

UGT2B7UDP-glucuronosyltransferase 2B7

inhibitor

CYP2B6Cytochrome P450 2B6

substrate

CYP2C9Cytochrome P450 2C9

substrate

CYP3A4Cytochrome P450 3A4

substrate

CYP2E1Cytochrome P450 2E1

inhibitor

UGT1A1UDP-glucuronosyltransferase 1A1

inhibitor

UGT1A3UDP-glucuronosyltransferase 1A3

inhibitor

CYP2C19Cytochrome P450 2C19

substrate

Scientific references(5)

Rickels K.

The clinical use of hypnotics: indications for use and the need for a variety of hypnotics.

Acta Psychiatrica Scandinavica

198674(S332):132-141. doi: 10.1111/j.1600-0447.1986.tb08990.x

PMID: 2883820 DOI: 10.1111/j.1600-0447.1986.tb08990.x

Robertson M.D., Drummer O.H.

Postmortem Drug Metabolism by Bacteria.

Journal of Forensic Sciences

199540(3):382-386. doi: 10.1520/jfs13791j

PMID: 7782744 DOI: 10.1520/jfs13791j

Oelschlager H.

Chemical models of vitrinite reflectance evolution.

Geologische Rundschau

198978(1):349-359. doi: 10.1007/bf01988369

PMID: 2570451 DOI: 10.1007/bf01988369

Usami N., Yamamoto T., Shintani S., Ishikura S., Higaki Y., Katagiri Y., Hara A.

Substrate Specificity of Human 3(20).

ALPHA

-Hydroxysteroid Dehydrogenase for Neurosteroids and Its Inhibition by Benzodiazepines.. Biological and Pharmaceutical Bulletin. 200225(4):441-445. doi: 10.1248/bpb.25.441

PMID: 11995921 DOI: 10.1248/bpb.25.441

Tokunaga S., Takeda Y., Shinomiya K., Hirase M., Kamei C.

Effects of Some H1-Antagonists on the Sleep-Wake Cycle in Sleep-Disturbed Rats.

Journal of Pharmacological Sciences

2007103(2):201-206. doi: 10.1254/jphs.fp0061173

PMID: 17287588 DOI: 10.1254/jphs.fp0061173

ATC classification(1 code)

ATC N05CD03

Affected organisms(1)

Humans and other mammals

International brands(5)

Experimental properties(2)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Flunitrazepam

DB01544

CAS number

1622-62-4

UNII (FDA)

620X0222FQ

InChI Key (molecular fingerprint)

PPTYJKAXVCCBDU-UHFFFAOYSA-N

Additional database identifiers

ChEBI

31622

PubChem Compound

3380

PubChem Substance

46504553

KEGG Drug

D01230

ChemSpider

3263

BindingDB

25878

PharmGKB

PA164781320

Therapeutic Targets Database

DAP000931

Wikipedia

Flunitrazepam

ChEMBL

CHEMBL13280

ZINC

ZINC000003812994

RxCUI

4460

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4078

GenAtlas

GABRA4

GeneCards

GABRA4

GenBank Gene Database

U30461

GenBank Protein Database

905393

IUPHAR

407

Guide to Pharmacology

407

UniProtKB

P48169

UniProt Accession

GBRA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4080

GenAtlas

GABRA6

GeneCards

GABRA6

GenBank Gene Database

S81944

GenBank Protein Database

1470364

IUPHAR

409

Guide to Pharmacology

409

UniProtKB

Q16445

UniProt Accession

GBRA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4081

GenAtlas

GABRB1

GeneCards

GABRB1

GenBank Gene Database

X14767

GenBank Protein Database

31635

IUPHAR

410

UniProtKB

P18505

UniProt Accession

GBRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4082

GenAtlas

GABRB2

GeneCards

GABRB2

GenBank Gene Database

S67368

GenBank Protein Database

455946

IUPHAR

411

UniProtKB

P47870

UniProt Accession

GBRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4083

GenAtlas

GABRB3

GeneCards

GABRB3

GenBank Gene Database

M82919

GenBank Protein Database

182925

IUPHAR

412

Guide to Pharmacology

412

UniProtKB

P28472

UniProt Accession

GBRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4084

GeneCards

GABRD

GenBank Gene Database

AF016917

GenBank Protein Database

2388693

UniProtKB

O14764

UniProt Accession

GBRD_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4085

GeneCards

GABRE

GenBank Gene Database

U66661

GenBank Protein Database

1857126

UniProtKB

P78334

UniProt Accession

GBRE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4089

GeneCards

GABRP

GenBank Gene Database

U95367

GenBank Protein Database

2197001

UniProtKB

O00591

UniProt Accession

GBRP_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14454

GeneCards

GABRQ

GenBank Gene Database

AF189259

GenBank Protein Database

7861736

UniProtKB

Q9UN88

UniProt Accession

GBRT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1158

GenAtlas

TSPO

GeneCards

TSPO

GenBank Gene Database

M36035

GenBank Protein Database

306883

Guide to Pharmacology

2879

UniProtKB

P30536

UniProt Accession

TSPO_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2610

GenAtlas

CYP2A6

GeneCards

CYP2A6

GenBank Gene Database

X13897

Guide to Pharmacology

1321

UniProtKB

P11509

UniProt Accession

CP2A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12554

GeneCards

UGT2B7

GenBank Gene Database

J05428

GenBank Protein Database

340080

UniProtKB

P16662

UniProt Accession

UD2B7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12530

GeneCards

UGT1A1

GenBank Gene Database

M57899

GenBank Protein Database

184473

Guide to Pharmacology

2990

UniProtKB

P22309

UniProt Accession

UD11_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12535

GeneCards

UGT1A3

GenBank Gene Database

M84127

GenBank Protein Database

340135

UniProtKB

P35503

UniProt Accession

UD13_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Flunitrazepam 1mg tablets

Legal requirements

Other medicines in this category

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science
12

Chemical identifiers

Flunitrazepam

Additional database identifiers

DrugBank citations

Flunitrazepam 1mg tablets

Controlled drug information

Legal requirements

Other medicines in this category

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science12

Chemical identifiers

Flunitrazepam

Additional database identifiers

DrugBank citations

Deep science
12